Y-mAbs Therapeutics (NASDAQ:YMAB) Rating Reiterated by Zacks Investment Research

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “hold” rating reissued by Zacks Investment Research in a research note issued to investors on Saturday, Zacks.com reports.

According to Zacks, “Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company’s product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA. “

YMAB has been the subject of several other research reports. HC Wainwright set a $40.00 price target on Y-mAbs Therapeutics and gave the company a “buy” rating in a report on Monday, August 26th. Wedbush initiated coverage on Y-mAbs Therapeutics in a report on Tuesday, September 3rd. They issued an “outperform” rating and a $38.00 price target for the company. Finally, Cowen reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a report on Monday, July 1st. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $32.50.

Y-mAbs Therapeutics stock traded up $0.98 during trading hours on Friday, hitting $26.05. The stock had a trading volume of 141,713 shares, compared to its average volume of 174,397. The company has a 50-day moving average of $27.41 and a two-hundred day moving average of $24.29. The company has a quick ratio of 9.04, a current ratio of 9.04 and a debt-to-equity ratio of 0.02. The company has a market cap of $864.84 million and a PE ratio of -17.37. Y-mAbs Therapeutics has a fifty-two week low of $15.17 and a fifty-two week high of $32.27.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.05). As a group, analysts forecast that Y-mAbs Therapeutics will post -2.1 EPS for the current fiscal year.

In other news, insider Thomas Gad sold 4,000 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $21.78, for a total value of $87,120.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Johan Wedell-Wedellsborg sold 89,166 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $26.58, for a total value of $2,370,032.28. The disclosure for this sale can be found here. Over the last three months, insiders sold 348,010 shares of company stock valued at $9,425,028. 38.40% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Artal Group S.A. acquired a new position in shares of Y-mAbs Therapeutics in the 2nd quarter worth approximately $9,148,000. AXA acquired a new position in shares of Y-mAbs Therapeutics in the 2nd quarter worth approximately $3,560,000. Alps Advisors Inc. acquired a new position in shares of Y-mAbs Therapeutics in the 2nd quarter worth approximately $1,637,000. Cormorant Asset Management LP raised its holdings in shares of Y-mAbs Therapeutics by 39.8% in the 2nd quarter. Cormorant Asset Management LP now owns 1,000,000 shares of the company’s stock worth $22,870,000 after buying an additional 284,518 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Y-mAbs Therapeutics in the 2nd quarter worth approximately $956,000. 32.06% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Further Reading: How to start trading in the forex market?

Get a free copy of the Zacks research report on Y-mAbs Therapeutics (YMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.